Nonsteroidal anti-inflammatory drugs (NSAIDs) are correlated with better overall survival in patients with head and neck squamous cell carcinoma (HNSCC) ...
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head and neck cancer treatment.